Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Change in Receivables of -$337000.0 for Q1 2026, down 116.96% year-over-year from $2.0 million in Q1 2025, and up 78.7% quarter-over-quarter from -$1.6 million in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Change in Receivables (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Change in Receivables for 11 consecutive years, with -$337000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 116.96% year-over-year to -$337000.0; the TTM figure through Mar 2026 stood at -$1.4 million (up 94.7% YoY), while the FY2025 annual figure was $951000.0, up 103.4% from the prior year.
- Change in Receivables climbed to -$337000.0 in Q1 2026 per NTLA's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Change in Receivables topped out at $30.0 million in Q4 2023 and bottomed at -$24.1 million in Q2 2024.
- Historically, Change in Receivables has averaged $417647.1 across 5 years, with a median of -$29000.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Receivables jumped 11850.98% — and 2024, when it tumbled 16059.6%.
- Intellia Therapeutics' Change in Receivables stood at -$255000.0 in 2022, then surged by 11850.98% to $30.0 million in 2023, then plunged by 101.12% to -$337000.0 in 2024, then slumped by 369.44% to -$1.6 million in 2025, then soared by 78.7% to -$337000.0 in 2026.
- Business Quant data shows NTLA's Change in Receivables at -$337000.0 in Q1 2026, -$1.6 million in Q4 2025, and -$303000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -1.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.81 Mn |
| Mar 31, 2026 | -337,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | -337,000.00 |
| Sep 30, 2024 | -3.47 Mn |
| Jun 30, 2024 | -24.10 Mn |
| Mar 31, 2024 | -29,000.00 |
| Dec 31, 2023 | 29.97 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 151,000.00 |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | -255,000.00 |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | -230,000.00 |
| Dec 31, 2021 | -460,000.00 |
| Sep 30, 2021 | 498,000.00 |